120277-12-5

Basic information

• Product Name: 3-(BROMOMETHYL)-4-METHYLPYRIDINE
• Synonyms: 3-(BROMOMETHYL)-4-METHYLPYRIDINE;3-(BroMoMethyl)-4-Methylpyridine-HBr
• CAS NO: 120277-12-5
• Molecular Formula: C7H8BrN
• Molecular Weight: 186.05
• Mol File: 120277-12-5.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 251.9°C at 760 mmHg
• Flash Point: 106.1°C
• Appearance: /
• Density: 1.448g/cm³
• Vapor Pressure: 0.0317mmHg at 25°C
• Refractive Index: 1.564
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 4.99±0.18(Predicted)
• CAS DataBase Reference: 3-(BROMOMETHYL)-4-METHYLPYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(BROMOMETHYL)-4-METHYLPYRIDINE(120277-12-5)
• EPA Substance Registry System: 3-(BROMOMETHYL)-4-METHYLPYRIDINE(120277-12-5)

Safety Data

• Hazardous Substances Data: 120277-12-5(Hazardous Substances Data)

Usage

General Description

3-(Bromomethyl)-4-methylpyridine is a chemical compound with the molecular formula C7H8BrN. It is a substituted pyridine derivative that is commonly used as an intermediate in the synthesis of pharmaceuticals, agrochemicals, and other organic compounds. The compound is characterized by its bromine-substituted methyl group and methyl group attached to the pyridine ring. It is primarily used as a reagent in organic synthesis, particularly in the production of heterocyclic compounds. 3-(Bromomethyl)-4-methylpyridine is known for its high reactivity and selectivity in various chemical reactions, making it a valuable building block in the development of new chemical compounds.

InChI:InChI=1/C7H8BrN/c1-6-2-3-9-5-7(6)4-8/h2-3,5H,4H2,1H3

Upstream product

• 583-58-4 3,4-Lutidin 

Relevant articles and documents

[(3-Pyridylalkyl)piperidylidene]benzocycloheptapyridine derivatives as dual antagonists of PAF and histamine

A series of [(3-pyridylalkyl)piperidylidene]- and (nicotinoylpiperidylidene)benzocycloheptapyridine derivatives, Ia,b, were prepared and evaluated for PAF antagonist and H1 antihistamine activity. PAF antagonist activity was investigated by the in vitro PAF-induced platelet aggregation assay (PPA) and the in vivo PAF-induced hypotension test in rats (PH) and mortality test in mice (PM). For the evaluation of H1 antihistamine activity, the in vitro histamine-induced contraction of the guinea-pig ileum assay (HC) and the in vivo histamine-induced hypotension test (HH) in normotensive rats were used. The potential antiallergic activity of the compounds was evaluated using the active anaphylactic shock test in mice. These compounds are structurally related to loratadine (1) and were generated by replacement of the ethoxycarbonyl group of 1 with substituted 3- pyridylmethyl and nicotinoyl moieties. Both anti-PAF and H1 antihistamine activities have shown a high dependence on the exact nature and position of the substituent in the pyridine ring. Optimum structure 19 (UR-12592) incorporating a (5-methyl-3-pyridyl)methyl radical displayed an unique dual activity inhibiting both PAF-induced effects (PPA, IC50 = 3.7 μM; PH, ID50 = 0.44 mg/kg iv; PM, ID50 = 1.9 mg/kg po) and histamine-induced effects (HC, IC50 = 3.9 nM; HH, ID50 = 1.4 mg/kg iv). Furthermore, 19 was highly active in the passive cutaneous anaphylactic shock in rats (ID50 = 1.2 mg/kg po) and strongly protected mice and rats from mortality induced by endotoxin (ID50 = 1.2 and 0.5 mg/kg iv, respectively). Compound 19 showed itself to be devoid of CNS depressant effects, neither modifying spontaneous motor activity nor prolonging barbiturate-sleeping time in mice at a dose of 100 mg/kg po, and is now under development.